NASDAQ$NRC

NRC Health · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Announced fourth quarter and calendar year 2023 results, marked by revenue stability and increased diluted earnings per share.

NRC Health reported stable revenue of $38 million for the fourth quarter of 2023 compared to the same period in 2022, with diluted earnings per share increasing to $0.36 from $0.27. The company focused on cost control and strategic capital allocation, returning $55 million to stockholders through dividends and stock repurchases during 2023.

  • Revenue remained stable at $38 million compared to the same quarter last year, as new core sales offset reductions in non-core revenue.
  • Diluted earnings per share increased to $0.36 from $0.27, driven by new sales, cost control, and reduced share count.
  • The company returned $55 million to stockholders in 2023 through dividends and stock repurchases.
  • Capital allocation is expected to focus on growth and innovation initiatives, including facilities renovation and the regular quarterly dividend.

Headline financials

Total Revenue

$38M

Previous: $38.1M-0.4%
EPS (adj)

$0.36

Previous: $0.27+33.3%
Capital Expenditures

$3.77M

Previous: $1.97M+91.8%
Net Income

$8.86M

Previous: $27K+32707.4%
Operating Income

$11.7M

Previous: $6.7K+174661.2%
Gross Profit

$22.8M

Previous: $24.2M-5.7%
Stock-Based Comp

$258K

Previous: $290K-11.0%

Revenue & EPS history

NRC · Revenue · Quarterly

$38M

Q4 2023-0.4%vs Q4 2022

Forward guidance

The company plans to roll out new Market Experience, PX, CX, and EX products, ramp up sales, IT, and innovative product development resources with a focus on AI enabled solutions, and expand Human Understanding across the experience lifecycle.

Tailwinds

  • Roll out new Market Experience, PX, CX, and EX products.
  • Ramp up sales, IT, and innovative product development resources.
  • Focus on AI enabled solutions to improve efficiency.
  • Expand Human Understanding across the experience lifecycle.
  • Increase share across historical and expanded markets.

Headwinds

  • No specific negatives were mentioned in the provided text.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-0.9%

Avg return

Earnings day

-0.9%

Avg return

5 days after

-0.3%

Avg return

30 days after

54%

28 / 52 earnings

Positive

+16.1%

Q3 2025

Best reaction

-19.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.6%+7.9%+16.0%
Q4 2025-19.9%-27.2%-35.9%
Q3 2025+16.1%+17.0%+51.2%
Q2 2025+2.1%+4.8%+6.7%
Q1 2025+7.0%+7.6%+20.2%
Q4 2024-11.9%-11.0%-22.6%
Q3 2024+2.6%-2.1%+4.5%
Q2 2024-11.7%-9.3%-7.2%
Q1 2024-15.3%-11.6%-23.7%
Q4 2023+2.2%+0.6%+1.7%
Q3 2023-1.9%-0.3%-1.1%
Q2 2023+2.2%-0.4%-2.6%
Q1 2023-8.3%-5.2%-1.2%
Q4 2022+4.8%+5.3%-1.8%
Q3 2022-13.5%-8.3%-3.5%
Q2 2022-4.1%-7.4%-12.8%
Q1 2022-5.3%-3.6%+5.0%
Q4 2021-1.5%-4.5%-4.7%
Q3 2021+6.7%+6.7%-8.1%
Q2 2021-0.8%-0.2%+1.6%
Q1 2021-10.2%-5.1%-7.0%
Q4 2020-0.7%-3.9%+0.3%
Q3 2020+1.8%-0.1%-7.8%
Q2 2020-4.1%-1.0%-3.0%
Q1 2020+4.6%+10.3%+12.7%
Q4 2019+0.3%+1.8%-36.0%
Q3 2019-0.4%+0.2%+7.5%
Q2 2019+3.0%+2.6%+1.0%
Q1 2019+7.1%+13.1%+26.5%
Q4 2018+0.6%+2.7%+0.2%
Q3 2018+3.5%+2.4%+4.8%
Q2 2018-0.3%-0.3%+2.4%
Q1 2018+7.3%+5.5%+5.4%
Q4 2017-7.4%-7.9%-9.7%
Q3 2017-10.1%-11.5%-7.7%
Q2 2017+0.9%+1.7%+9.9%
Q1 2017+0.8%-3.4%-3.0%
Q4 2016-3.0%-4.9%+0.5%
Q3 2016-4.6%-1.0%+5.2%
Q2 2016+0.3%+2.3%+2.2%
Q1 2016+2.0%
Q4 2015+0.6%
Q3 2015+1.5%
Q2 2015-2.4%
Q1 2015+1.3%
Q4 2014-0.8%
Q3 2014+0.9%
Q2 2014+3.8%
Q1 2014+3.9%
Q4 2013+5.1%
Q3 2013+1.0%
Q2 2013-1.2%
Q1 2013
Q4 2012
Q2 2010
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q1 2011
Q3 2011
Q3 2010
Q4 2009
Q2 2011
Q4 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro